智通财经APP讯，同源康医药-B(02410)发布公告，张森泉先生(张先生)已提出辞任本公司独立非执行董 事(独立非执行董事)以投放更多时间从事其他商业事务，自2025年9月15日起生效。辞任后，张先生不 再担任董事会审计委员会主席、董事会薪酬与考核委员会成员及提名委员会成员。 ...

格隆汇9月15日丨同源康医药-B(02410.HK)宣布，张森泉已提出辞任公司独立非执行董事以投放更多时 间从事其他商业事务，自2025年9月15日起生效。辞任后，张森泉不再担任董事会审计委员会主席、董 事会薪酬与考核委员会成员及提名委员会成员。 ...

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 董事名單與其角色和職能 浙江同源康醫藥股份有限公司董事會（「董事會」）成員如下。 執行董事 董事會設立四個委員會。下表提供各董事會成員所在委員會的成員資料。 | | 委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 科學委員會 | | 吳豫生博士 | | | M | C | C | | 李鈞博士 | | M | | | M | | 顧虹博士 | | | | | | | 蔣鳴昱博士 | | | | | | | 何超先生 | | | | | | | 朱向陽博士 | | | | | | | 冷瑜婷博士 | | M | C | M | | | 許文青博士 | | | | | M | | 沈秀華博士 | | | | | | 附註： C 有關董事會委員會主席 吳豫生博士 非執行董事 李鈞博士 顧虹博士 蔣鳴昱博士 何超先生 朱向陽博士 獨立非執行董事 冷瑜婷博士 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 獨立非執行董事辭任 及 暫未能符合相關上市規則 浙江同源康醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，張 森泉先生（「張先生」）已提出辭任本公司獨立非執行董事（「獨立非執行董事」）以 投放更多時間從事其他商業事務，自2025年9月15日起生效。辭任後，張先生不 再擔任董事會審計委員會主席、董事會薪酬與考核委員會成員及提名委員會成 員。張先生已確認，彼與董事會及本公司之間並無意見分歧，亦概無有關其辭任 的事宜須提請本公司股東或香港聯合交易所有限公司（「聯交所」）垂注。 董事會謹藉此機會對張先生於其任職期間作出的寶貴貢獻致以衷心感謝。 董事長、執行董事兼總裁 吳豫生博士 香港，2025年9月15日 2 暫未能符合相關上市規則項下規定 張先生辭任後，本公司 ...

Core Insights - The 2025 World Lung Cancer Conference (WCLC) in Barcelona focuses on advancements in lung cancer research, clinical diagnosis, and innovative therapies, serving as a key platform for global lung cancer treatment innovation [1] Group 1: Clinical Trial Overview - The key registration trial for the drug Aido Tini (TY-9591) by company Same Source Pharmaceutical-B (02410) was selected for a Mini Oral presentation at WCLC 2025, highlighting its significance in the field [1] - The trial is an open-label, multi-center, randomized controlled phase II study targeting NSCLC patients with EGFR mutations (L858R or 19Del) and brain metastases, comparing the efficacy and safety of Aido Tini (160mg daily) against Osimertinib (80mg daily) [2] Group 2: Efficacy Results - As of February 28, 2025, the study enrolled 257 patients, with a mid-term analysis of 224 patients showing an intracranial objective response rate (iORR) of 92.8% for Aido Tini compared to 76.1% for Osimertinib, with a statistically significant P-value of 0.0006 [2] - Investigator-assessed iORR for Aido Tini was 91.0% versus 75.2% for Osimertinib, with a P-value of 0.002, indicating strong efficacy [3] Group 3: Safety Profile - The incidence of grade ≥3 treatment-related adverse events was 31.5% for Aido Tini and 15.0% for Osimertinib, with common severe adverse reactions including elevated creatine phosphokinase and QTc interval prolongation [3] - The incidence of interstitial lung disease (ILD) was 6.3% and QTc prolongation was 4.5%, both within manageable limits [3] Group 4: Market Potential - Currently, there are no approved third-generation EGFR-TKIs for NSCLC with brain metastases, positioning Aido Tini as a promising candidate to meet the clinical needs of this patient population [4] - The recognition of Aido Tini's efficacy and safety data at an international academic conference underscores its potential for clinical translation and commercial success in a supportive policy environment for innovative drug development in China [4]

Core Insights - The 2025 World Lung Cancer Conference (WCLC) in Barcelona focuses on advancements in lung cancer research, clinical treatment, and innovative therapies, serving as a key platform for global lung cancer treatment innovation [1] Group 1: Clinical Trial Overview - The key registration trial for the drug Aido Tini (TY-9591) was selected for a Mini Oral presentation at WCLC 2025, highlighting its significance in the field [1] - The trial is an open-label, multi-center, randomized controlled phase II study comparing Aido Tini (160mg daily) to Osimertinib (80mg daily) in untreated EGFR mutation-positive NSCLC patients with brain metastases [2] - A total of 257 patients with EGFR mutation-positive NSCLC and brain metastases were enrolled by February 28, 2025, with a mid-term analysis based on 224 patients showing a high intracranial objective response rate (iORR) of 92.8% for Aido Tini compared to 76.1% for Osimertinib [2] Group 2: Efficacy and Safety Results - The investigator-assessed iORR for Aido Tini was 91.0%, while for Osimertinib it was 75.2%, with a statistically significant difference (P=0.002) [3] - According to RANO-BM criteria, the confirmed iORR was 90.1% for Aido Tini and 74.3% for Osimertinib (P=0.0023) [3] - The incidence of grade ≥3 treatment-related adverse events was 31.5% for Aido Tini and 15.0% for Osimertinib, with the most common severe adverse reactions including elevated creatine phosphokinase and QTc interval prolongation [3] Group 3: Market Potential and Implications - Currently, there are no approved third-generation EGFR-TKIs for NSCLC with brain metastases, positioning Aido Tini as a promising candidate to meet the clinical needs of this patient population [4] - The recognition of Aido Tini's efficacy and safety data at an international academic conference underscores its clinical translation potential [4] - With supportive policies for innovative drug development in China, Aido Tini is expected to establish a solid foundation for future commercialization [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上巿股份 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,608,000 | RMB | | | 1 RMB | | 4,608,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 4,608,000 | RMB | | | 1 RMB | ...

Core Viewpoint - The revenue of Tongyuan Kang Pharmaceutical-B (02410.HK) is primarily dependent on the exclusive licensing agreement with Lijun Pharmaceutical for the development and commercialization of the multi-target small molecule tyrosine kinase inhibitor TY-2136b in Greater China, with no milestone payments triggered as of June 30, 2025 [1] Financial Performance - The company's revenue for the six months ending June 30, 2024, and June 30, 2025, is reported as RMB 0 [1] - Research and development costs for the six months ending June 30, 2025, amounted to RMB 88.758 million, a decrease of 35.6% compared to RMB 137.758 million for the same period in 2024, primarily due to reduced trial and testing expenses [1] - The loss for the six months ending June 30, 2025, decreased to RMB 114 million from RMB 220 million for the same period in 2024 [1]

Group 1 - The core point of the article is that Dr. Meng Xiaoying has resigned from her position as a non-executive director of the company, effective from August 31, 2025, to dedicate more time to other business commitments [1] Group 2 - The resignation indicates a shift in the company's board composition, which may impact its strategic direction and governance [1] - The company may need to consider appointing a new non-executive director to fill the vacancy left by Dr. Meng [1] - This change could reflect broader trends in the industry regarding board member commitments and the balancing of multiple business interests [1]

同源康医药-B(02410)公布，孟晓英博士已提出辞任公司非执行董事，自2025年8月31日起生效，以投放 更多时间从事其他业务承担。 ...